BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36759438)

  • 1. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
    Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
    Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors.
    Guibourg B; Cloarec E; Conan-Charlet V; Quintin-Roué I; Grippari JL; Le Flahec G; Marcorelles P; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):719-724. PubMed ID: 32187023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
    Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
    Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
    Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
    Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
    [No Abstract]   [Full Text] [Related]  

  • 6. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for NTRK-rearranged Tumors Using Immunohistochemistry: Comparison of 2 Different pan-TRK Clones in Melanoma Samples.
    Bourhis A; Redoulez G; Quintin-Roué I; Marcorelles P; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):194-196. PubMed ID: 30920961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls.
    Moura MS; Costa J; Velasco V; Kommoss F; Oliva E; Le Loarer F; McCluggage WG; Razack R; Treilleux I; Mills A; Longacre T; Devouassoux-Shisheboran M; Hostein I; Azmani R; Blanchard L; Hartog C; Soubeyran I; Khalifa E; Croce S
    Histopathology; 2024 Feb; 84(3):451-462. PubMed ID: 37988282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions.
    Adam J; Stang NL; Uguen A; Badoual C; Chenard MP; Lantuéjoul S; Maran-Gonzalez A; Robin YM; Rochaix P; Sabourin JC; Soubeyran I; Sturm N; Svrcek M; Vincent-Salomon A; Radosevic-Robin N; Penault-Llorca F
    Mod Pathol; 2023 Aug; 36(8):100192. PubMed ID: 37084942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
    Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
    Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for
    Macerola E; Proietti A; Poma AM; Vignali P; Sparavelli R; Ginori A; Basolo A; Elisei R; Santini F; Basolo F
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
    Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
    Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial.
    De Winne K; Sorber L; Lambin S; Siozopoulou V; Beniuga G; Dedeurwaerdere F; D'Haene N; Habran L; Libbrecht L; Van Huysse J; Weynand B; Wouters K; Pauwels P; Zwaenepoel K
    Virchows Arch; 2021 Feb; 478(2):283-291. PubMed ID: 32915263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
    Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
    Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study.
    Hyrcza MD; Martins-Filho SN; Spatz A; Wang HJ; Purgina BM; Desmeules P; Park PC; Bigras G; Jung S; Cutz JC; Xu Z; Berman DM; Sheffield BS; Cheung CC; Leduc C; Hwang DM; Ionescu D; Klonowski P; Chevarie-Davis M; Chami R; Lo B; Stockley TL; Tsao MS; Torlakovic E
    Mod Pathol; 2024 Jan; 37(1):100384. PubMed ID: 37972928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
    Su YJ; Lee YH; Jin YT; Hsieh MS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
    Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
    J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
    Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
    Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.